NRX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.04 USD | +3.75% |
|
+44.76% | -33.91% |
| May. 06 | NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data | DJ |
| May. 06 | NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 31.68M |
|---|---|---|---|---|---|
| Net income 2024 * | -21M | Net income 2025 * | -21M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.39
x | P/E ratio 2025 * |
-1.45
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.76% |
More Fundamentals
* Assessed data
More news
Latest transcript on NRx Pharmaceuticals, Inc.
More press releases
More news
| 1 day | +3.75% | ||
| 1 week | +44.76% | ||
| Current month | +17.83% | ||
| 1 month | -44.73% | ||
| 3 months | -40.62% | ||
| 6 months | -7.85% | ||
| Current year | -33.91% |
1 week
2.32
3.75
1 month
1.905.20
Current year
1.907.33
1 year
1.9012.00
3 years
1.90488.00
5 years
1.90769.90
10 years
1.90769.90
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Willard
CEO | Chief Executive Officer | 63 | 22-07-11 |
Jonathan Javitt
FOU | Founder | 67 | 17-09-17 |
Richard Narido
DFI | Director of Finance/CFO | 46 | 23-09-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jonathan Javitt
FOU | Founder | 67 | 17-09-17 |
Stephen Willard
CEO | Chief Executive Officer | 63 | 22-07-11 |
Janet Rehnquist
BRD | Director/Board Member | - | Dec. 26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 3.04 | +3.75% | 361,172 |
| 24-05-09 | 2.93 | +3.90% | 590,434 |
| 24-05-08 | 2.82 | +0.36% | 399,808 |
| 24-05-07 | 2.81 | -8.17% | 1,069,439 |
| 24-05-06 | 3.06 | +45.71% | 9,310,734 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.04
USD
Average target price
35
USD
Spread / Average Target
+1,051.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.91% | 31.68M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- BRPA Stock
